Main Objectives. This was a randomized, double-blind trial of fondaparinux in patients with STEMI. The primary objective of the study was to evaluate the impact of fondaparinux as an anticoagulant ...

A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a ...

While fondaparinux has been available for nearly a decade, its use has not been nearly as extensive as the use of LMWHs. Thus, clinical experience with this agent and outcomes data are far more ...

Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...